Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Schalper, K.A. (Kurt A.), Rodriguez-Ruiz, M.E. (María Esperanza), Diez-Valle, R. (Ricardo), López-Janeiro, Á. (Álvaro), Porciuncula, A. (Angelo), Idoate, M.A. (Miguel Ángel), Inoges, S. (Susana), Andrea, C.E. (Carlos Eduardo) de, Lopez-Diaz-de-Cerio, A. (Ascensión), Tejada-Solis, S. (Sonia), Berraondo, P. (Pedro), Villarroel-Espindola, F. (Franz), Choi, J. (Jungmin), Gurpide, A. (Alfonso), Giraldez, M. (Miriam), Goicoechea, I. (Iosune), Gallego-Perez-Larraya, J. (Jaime), Fernandez-Sanmamed, M. (Miguel), Perez-Gracia, J.L. (Jose Luis), Melero, I. (Ignacio)
التنسيق: info:eu-repo/semantics/article
اللغة:eng
منشور في: Nature Publishing Group 2024
الموضوعات:
Materias Investigacion::Ciencias de la Salud::Oncología
Glioblastoma
Neoadjuvant nivolumab
الوصول للمادة أونلاين:https://hdl.handle.net/10171/68722

الانترنت

https://hdl.handle.net/10171/68722

مواد مشابهة